Barriers in inflammatory bowel disease care in Central and Eastern Europe: a region-specific analysis

Inflammatory bowel diseases (IBD), including Crohn’s disease and ulcerative colitis, are chronic immune-mediated diseases with a high incidence and prevalence in Europe. Since these are diseases with associated disability, they require complex management and the availability of high-quality healthcare resources. We focused on the analysis of IBD care in selected countries of Central and Eastern Europe (Croatia, the Czech Republic, Hungary, Moldova, Poland, Romania and Slovakia) targeting the availability and reimbursement of diagnostic and therapeutic modalities, the role of IBD centers and also education and research in IBD. As part of the analysis, we created a questionnaire of 73 statements organized in three topics: (1) diagnostics, follow-up and screening, (2) medications and (3) IBD centers. The questionnaire was filled out by co-authoring IBD experts from individual countries, and then the answers and comments on the questionnaire were analyzed. We identified that despite the financial burden, which still partially persists in the region, the availability of some of the cost-saving tools (calprotectin test, therapeutic drug monitoring) differs among countries, mainly due to variable reimbursement from country to country. In most participating countries, there also remains a lack of dedicated dietary and psychological counseling, which is often replaced by recommendations offered by gastroenterologists. However, there is adequate availability of most of the currently recommended diagnostic methods and therapies in each participating country, as well as the implementation of established IBD centers in the region. © The Author(s), 2023

Atopy Patch Test in the Diagnosis of Food Allergy in Children with Atopic Dermatitis

Atopic eczema/dermatitis syndrome (AEDS) is one of the most common chronic allergic diseases in children. Among the allergens found to be relevant in AEDS, aeroallergens and food allergens are the most important. The exposure of these patients to their relevant protein allergens can trigger an exacerbation or maintain the disease. AEDS is frequently associated with food allergy, which complicates the management in approximately 40% of these children. Atopy patch test (APT) can help in detecting food allergies in children with AEDS. The earliest publication on patch testing in eczema was described in 1937 by Rostenberg, but the first controlled clinical trial was provided by Mitchell in 1982. APT with food allergens were introduced into clinical use in 1996 by the group of Isolauri. APT test is performed epicutaneously with typical immediate-type allergens (aeroallergens or foods). As a number of apparently minor test modifications greatly influence the sensitivity, specificity, and reproducibility of the APT, the European Task Force on Atopic Dermatitis (ETFAD) has developed a standardized APT technique. APT has developed into a valuable additional tool in the diagnostic work-up of food allergy in infants and children with atopic dermatitis

Bronchial Asthma and Obesity in Childhood

Bronchial asthma and obesity is among a group of multietiologic complex diseases which influence each other in their origin, and development. The impact on the patient‘s quality of life and prognosis is significant, health costs included. Because of the increasing prevalence worldwide, there has been an increase in the amount of studies dealing with reciprocal associations between asthma and obesity

New Aspects in Respiratory Epithelium Diagnostics Using Virtual Instrumentation

Subject of interest is trajectory analysis of moving object. Object is represented by respiratory epithelium cilium. Cilium trajectory and another parameter – beating frequency – are very important parameters in respiratory apparatus diagnostics. Main method of motion detection is Geometric Matching and gray level variance capturing. Primary experiments were taken on video phantoms simulating cilia movement using two camera systems: Marlin and PONTOS. All the phantoms were processed in LabVIEW development environment. Article focuses on acquisition conditions, preprocessing of videosequences and basic measurement on acquired phantoms

Young and Exhausted

Chronic fatigue syndrome/myalgic enceph-alomyelitis (CFS/ME) is a complex [...

Endovascular Treatment of Gastrointestinal Hemorrhage

Background and Objectives: Severe non-variceal gastrointestinal bleeding is a life-threatening condition with complicated treatment if endoscopic therapy fails. In such cases, transcatheter arterial embolization is recommended. The technical and clinical effects of this technique were analyzed in this group of patients, as well as its complication rate and 30-day mortality. Materials and Methods: Patient data over a one-decade period (from 2010 to 2019) were analyzed retrospectively; 27 patients (18 men and 9 women; median age 61 years) treated by endovascular embolization in our institution, with clinically significant gastrointestinal hemorrhage after unsuccessful or impossible endoscopic treatment, were identified, and their data were collected. Results: The source of bleeding was found in 88% of patients, but embolization was performed in 96% of them. The overall technical success rate was 96.8%, and the clinical success was 88.5%. Re-bleeding occurred in eight cases, five of whom had re-embolization that was technically successful in four cases. The incidence of re-bleeding was significantly higher in patients with two or more comorbidities (p = 0.043). There was one serious complication (4%) in the group, and minor difficulties occurred in 18% of patients; 30-day mortality reached 22%. Mortality was significantly higher in the group of patients with re-bleeding (p = 0.044). Conclusions: Transcatheter arterial embolization is a mini-invasive method with high technical success in patients with endoscopically untreatable gastrointestinal bleeding; it is also suitable for high-risk cases. Mortality (to a significant extent) depends on the occurrence of re-bleeding and the patient’s comorbidities